Solvay Pharma
Solvay Pharma, a prominent division of Solvay Group, is headquartered in France and operates extensively across Europe, North America, and Asia. Established in 1995, the company has made significant strides in the pharmaceutical industry, focusing on innovative treatments in areas such as central nervous system disorders, women's health, and rare diseases. Renowned for its commitment to research and development, Solvay Pharma offers a range of unique products that address unmet medical needs, setting it apart in a competitive market. With a strong emphasis on sustainability and patient-centric solutions, the company has achieved notable recognition for its contributions to healthcare. As a key player in the pharmaceutical landscape, Solvay Pharma continues to advance its mission of improving patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Solvay Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solvay Pharma's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Solvay Pharma's reported carbon emissions
In 2022, Solvay Pharma reported total carbon emissions of approximately 34,500,000,000 kg CO2e. This figure includes 9,200,000,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources. Scope 2 emissions, primarily from purchased electricity and steam, totalled about 1,100,000,000 kg CO2e. The majority of emissions, approximately 24,200,000,000 kg CO2e, fall under Scope 3, which encompasses indirect emissions from the value chain, including categories such as purchased goods and services, use of sold products, and end-of-life treatment of sold products. Comparatively, in 2021, total emissions were about 36,800,000,000 kg CO2e, indicating a reduction in emissions of approximately 2,300,000,000 kg CO2e year-on-year. This trend suggests a commitment to decreasing their carbon footprint, although specific reduction targets or initiatives have not been disclosed. Solvay Pharma has not reported any specific science-based targets (SBTi) or climate pledges, indicating a potential area for future commitment. The emissions data is not cascaded from any parent organization, reflecting Solvay Pharma's independent reporting on its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 11,400 | 00,000 | 00,000 | 00,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 2,800 | 0,000 | 0,000 | 0,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | 11,920 | 00,000 | 0,000 | 0,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Solvay Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
